1. Introduction
===============

3-n-butylphthalide (NBP), approved by the China Food and Drug Administration for the treatment of acute ischemic stroke, is a type of compound isolated from the seeds of Chinese celery ([@b1-br-0-0-1246]). The molecular structure of NBP is presented in [Fig. 1](#f1-br-0-0-1246){ref-type="fig"}. Therapy using NBP has been recommended by Chinese guidelines for acute ischemic stroke ([@b2-br-0-0-1246]). A randomized double-blind trial (clinical trial no. ChiCTR-TRC-09000483) reported that NBP significantly improves clinical outcomes, including the modified Rankin Scale ([@b3-br-0-0-1246]) and National institute of Health Stroke Scale scores ([@b4-br-0-0-1246]), of patients who experienced ischemic stroke ([@b5-br-0-0-1246]). In addition, a study demonstrated that NBP therapy persistently increases the level of endothelial progenitor cells in peripheral blood, ameliorate cerebral blood flow and improve neuronal functions ([@b6-br-0-0-1246]). Furthermore, NBP has been reported to be a safe treatment for cerebral ischemia stroke ([@b5-br-0-0-1246]). A study has indicated that NBP exhibits protective effects in several neurodegenerative diseases ([@b8-br-0-0-1246]). However, to the best of our knowledge, the neuroprotective mechanism of NBP remains unclear. Therefore, the present review discusses the potential mechanism of neuroprotective effects of NBP. The aim of the current review is to provide further understanding regarding the advances of NBP.

2. NBP inhibits the inflammatory reaction
=========================================

Inflammation, a complex biological response to injury, is associated with neurodegenerative diseases, including Alzheimer\'s disease, Parkinson\'s disease (PD), multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury (TBI) and more ([@b9-br-0-0-1246]). NBP has exhibited anti-inflammatory effects in various models of these diseases and certain mechanisms have been identified. NBP has been reported to reduce the inflammatory reaction by inhibiting nucleotide binding oligomerization domain like receptor protein 3-inflammasome microglia activation and mitigating the Alzheimer\'s-like pathology via the nuclear factor erythroid-2-related factor 2-thioredoxin-interacting protein-TXNIP-thioredoxin axis in an APP/PS1 mouse model ([@b12-br-0-0-1246],[@b13-br-0-0-1246]). Furthermore, NBP inhibited the inflammatory reaction in lipopolysaccharide (LPS)-induced rats via inhibition of c-Jun N-terminal kinase activation and the NF-κB pathway ([@b14-br-0-0-1246],[@b15-br-0-0-1246]). NBP was reported to improve dyskinesia in a LPS-induced PD mouse model via a reduction in the loss of dopaminergic neurons, activation of mouse microglia, an increase in TNF-α levels and α-synuclein deposition in the black substantia of the mouse midbrain ([@b16-br-0-0-1246]). Additionally, NBP-treatment reduces NF-κB activation following TBI ([@b17-br-0-0-1246]), and NBP also inhibits the inflammatory reaction via the same pathway in spontaneously hypertensive rats ([@b18-br-0-0-1246]). Notably, a number of studies have indicated that NBP inhibits the inflammatory reaction in other neuroassociated experimental models, such as an experimental model of autoimmune encephalomyelitis of microglia or autoimmune myositis in guinea pigs ([@b19-br-0-0-1246],[@b20-br-0-0-1246]). In addition, NBP-treatment has been demonstrated to significantly ameliorate cerebral ischemia reperfusion-induced brain injury of Sprague-Dawley (SD) rats by inhibiting toll like receptor 4/NF-κB-associated inflammation ([@b21-br-0-0-1246]). NBP attenuates advanced glycation end products-induced endothelial dysfunction by ameliorating inflammatory responses ([@b22-br-0-0-1246]). In summary, there is some understanding regarding the mechanism of NBP in the inhibition of inflammation.

3. NBP reduces mitochondrial oxidative stress
=============================================

Mitochondria, the site of oxidative metabolism in eukaryotes, produce energy through the oxidation of carbohydrates, fats and amino acids ([@b23-br-0-0-1246]). Therefore, mitochondrial dysfunction in the form of oxidative stress may contribute to the pathogenesis of various neurodegenerative diseases ([@b24-br-0-0-1246]). Oxidative stress is considered a condition that is caused by an imbalance between pro- and antioxidant factors, which leads to molecular and cellular damage ([@b25-br-0-0-1246]). Oxidative stress serves an essential role in the development of age-related diseases ([@b26-br-0-0-1246]). NBP exhibits a cumulative beneficial effect on the process of mitochondrial damage ([@b27-br-0-0-1246]). This section will discuss the mechanisms involved in mitochondrial oxidative stress.

Recently, NBP exhibited a powerful effect on antioxidant stress in some different models. NBP inhibited oxidative stress in K141N-induced SH-SY5Y cells and in LPS-induced rats through activation of the Kelch-like ECH-associating protein 1 Nrf2-related factor 2-antioxidant response element signaling pathway ([@b15-br-0-0-1246],[@b28-br-0-0-1246]). Similarly, NBP reduced oxidative damage to provide neuroprotection in mice following TBI and in rats following carbon monoxide poisoning ([@b29-br-0-0-1246],[@b30-br-0-0-1246]). In addition, NBP protects against cerebral ischemia-reperfusion injury by decreasing antioxidant stress via the ERK signaling pathway ([@b31-br-0-0-1246]). NBP also protects against H~2~O~2~-induced injury in neural stem cells by activation of the PI3K/Akt and the Mash1 signaling pathways ([@b32-br-0-0-1246]). Furthermore, NBP has been reported to increase superoxide dismutase and catalase activity, and reduce malondialdehyde activity in the experimental autoimmune myositis (EAM) model, NBP directly protects muscle mitochondria and muscle cells from oxidative damage ([@b33-br-0-0-1246]). However, the protective effect of NBP on mitochondrial function is not only limited to neurodegeneration, but also appears in cardiovascular diseases. A study suggested that NBP exerts a cardioprotective effect on cardiac ischemic injury via the regulation of mitochondrial function both using *in vivo* and *in vitro* experiments ([@b34-br-0-0-1246]). In summary, the antioxidant effect of NBP has been widely recognized.

4. NBP regulates apoptosis and autophagy
========================================

Apoptosis and autophagy are basic biological phenomena of cells, which serve essential roles in removing abnormal cells in multicellular organisms. Disorders in the apoptosis and autophagy processes may cause the occurrence of neuropathy ([@b35-br-0-0-1246]). The neuroprotective effect of NBP via the regulation of apoptosis and autophagy has been demonstrated. Treatment with NBP has been reported to reduce apoptotic cell death by increasing the levels of cleaved caspase-3 and caspase-9 following TBI ([@b17-br-0-0-1246]). Furthermore, NBP blocks neural apoptosis in areas surrounding cortical contusions on the brain that are induced by TBI ([@b29-br-0-0-1246]). The neuroprotective mechanism of NBP involves the mitochondrial apoptotic pathway. NBP inhibits HSPB8 K141N mutation-induced neurotoxicity, attenuates β-amyloid-induced toxicity in SH-SY5Y cells, and protects rat cardiomyocytes from ischemia or reperfusion through regulating mitochondrion-mediated apoptosis ([@b28-br-0-0-1246],[@b36-br-0-0-1246],[@b37-br-0-0-1246]). Furthermore, certain studies have demonstrated the inhibition of apoptosis by NBP via the Akt pathway. One study reported that NBP activates Akt/mTOR signaling to inhibit neuronal apoptosis and autophagy in mice with repeated cerebral ischemia reperfusion injury ([@b38-br-0-0-1246]). Another study demonstrated that NBP improves cognitive impairment of APP/PS1 mice by inhibiting apoptosis via the PI3K/AKT pathway ([@b39-br-0-0-1246]). Additionally, NBP reduces the number of apoptotic cells by regulating Bcl-2 in HUVECs and an EAM model ([@b22-br-0-0-1246],[@b33-br-0-0-1246]).

5. NBP resists endoplasmic reticulum stress
===========================================

ERS is characterized by incorrect folding and aggregation of unfolded proteins in the endoplasmic reticulum lumen and a disturbance of the calcium balance, which can activate the unfolded protein response and lead to disturbance of the cell function and cell death ([@b40-br-0-0-1246]). In recent years, certain studies have reported an anti-ERS effect of NBP. One study demonstrated that NBP inhibits doxorubicin-induced ERS in SD rats ([@b41-br-0-0-1246]). In addition, NBP alleviates vascular cognitive impairment by regulating ERS and the Sonic hedgehog/Patched homolog 1 signaling pathway in SD rats ([@b42-br-0-0-1246]). Both of these studies agreed that NBP attenuates ERS through regulating the expression of 78-kDa glucose-regulated protein (GRP78), CCAAT-enhancer binding protein homologous protein (CHOP) and caspase-12. Furthermore, NBP also inhibits ERS by attenuating activating transcription factory (ATF)-4, ATF-6, X-box binding protein 1, protein disulfide isomerase, GRP78, CHOP and cleaved-caspase-12 in a spinal cord injury (SCI) model, which may improve functional recovery and prevent disruption of the blood-spinal cord barrier ([@b43-br-0-0-1246],[@b44-br-0-0-1246]). However, this mechanism has only recently been identified; therefore, there is limited literature about it. Further research on this mechanism may lead to new findings.

6. NBP decreases abnormal protein deposition
============================================

Abnormal protein deposition is closely associated with numerous neurodegenerative diseases ([@b45-br-0-0-1246]), such as Alzheimer\'s disease, which is associated with amyloid-β (Aβ) and tau proteins; and PD, which is associated with α-synuclein ([@b46-br-0-0-1246]). A study has demonstrated that NBP significantly reduces total cerebral Aβ plaque deposition and lowers Aβ levels in brain homogenates in a triple-transgenic mouse model of Alzheimer\'s disease via directing amyloid precursor protein processing toward a non-amyloidogenic pathway ([@b47-br-0-0-1246]). Furthermore, NBP treatment inhibited tau hyperphosphorylation in AβPP/PS1 mice, which may improve cognitive impairment ([@b48-br-0-0-1246]). NBP enhances a 1-methyl-4-phenylpyridiniumion-induced cellular model and a LPS-induced mice model of PD via reducing the accumulation of α-synuclein ([@b16-br-0-0-1246],[@b49-br-0-0-1246]). However, the molecular mechanisms of how NBP reduces the accumulation of α-synuclein and inhibits tau hyperphosphorylation remain unclear. Furthermore, to the best of our knowledge, there is no associated study that provides the clinical evidence that NBP is effective in multiple sclerosis or Lewy body dementia via attenuating abnormal protein deposition. Potentially, new findings can be revealed in additional neurodegenerative diseases.

7. Conclusion
=============

In summary, current studies suggest that NBP serves a neuroprotective role through inhibiting inflammation, protecting mitochondrial function, alleviating oxidative stress, regulating apoptosis, resisting ERS and decreasing the abnormal protein deposition ([Fig. 2](#f2-br-0-0-1246){ref-type="fig"}). Details on specific molecular mechanisms are presented in [Table I](#tI-br-0-0-1246){ref-type="table"}. Taken together, it is suggested that NBP provides a promising therapeutic strategy for neurodegenerative diseases. In further studies, the mechanism of action of NBP may be further clarified, and the understanding regarding its potential uses may be expanded.
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Neuroprotective mechanisms of 3-n-butylphthalide.

  A, Inflammation inhibition                                                                                                                                                                               
  ------------------------------------------------ ------------------- -------------------------------------------------------- -------------------------------------------------------------------------- ----------------------
  Wang *et al*, 2018                               APP/PS1 mice        Transgenic                                               NLRP3 inflammasome activation inhibition                                   ([@b13-br-0-0-1246])
                                                   A172, SH-SY5Y       LPS induced                                              NLRP3 inflammasome activation inhibition                                    
  Yang *et al*, 2018                               SD rats             LPS induced                                              NF-κB pathway inhibition                                                   ([@b14-br-0-0-1246])
  Zhao *et al*, 2016                               C57BL/6 mice        LPS induced                                              Downregulation of JNK activation                                           ([@b15-br-0-0-1246])
  Zhao *et al*, 2017                               C57BL/6 mice        Traumatic brain injury                                   NF-κB pathway inhibition                                                   ([@b17-br-0-0-1246])
  Wang *et al*, 2018                               EAE                 Neuroantigen-specific proinflammatory T cells induced    Suppression of PGAM5                                                       ([@b19-br-0-0-1246])
  Zhang *et al*, 2016                              SD rats             Cerebral ischemia reperfusion induced                    Increased HGF expression                                                   ([@b21-br-0-0-1246])
  Liu *et al*, 2017                                HUVECs              Advanced glycation end product induced                   RAGE/NF-κB pathway inhibition                                              ([@b22-br-0-0-1246])
  B, Reduction of mitochondrial oxidative stress                                                                                                                                                           
  Author, year                                     Study subject       Method                                                   Molecular mechanism                                                        Refs.
  Yang *et al*, 2017                               SH-SY5Y             Missense mutations                                       Increased Nrf2 expression                                                  ([@b28-br-0-0-1246])
  Liu *et al*, 2017                                ICR mice            Traumatic brain injury                                   Nrf2-ARE pathway activation                                                ([@b29-br-0-0-1246])
  Li *et al*, 2015                                 SD rats             Carbon monoxide poisoned                                 Keap1/Nrf2 pathway activation                                              ([@b30-br-0-0-1246])
  Zhu *et al*, 2018                                ICR mice            Cerebral ischemia reperfusion injury                     ERK signaling inhibition                                                   ([@b31-br-0-0-1246])
  Wang *et al*, 2018                               NSCs from SD rats   Hydrogen peroxide induced                                PI3K/Akt and Mash1 pathway activation                                      ([@b32-br-0-0-1246])
  Chen *et al*, 2017                               Guinea pigs         Experimental autoimmune myositis                         Enhanced Na^+^-K^+^ and Ca2^+^-Mg^2+^ ATPase activities                    ([@b33-br-0-0-1246])
  Tian *et al*, 2017                               H9C2                Hydrogen peroxide induced                                Enhanced Nrf-1 and TFAM expression                                         ([@b34-br-0-0-1246])
  C, Regulation of apoptosis and autophagy                                                                                                                                                                 
  Author, year                                     Study subject       Method                                                   Molecular mechanism                                                        Refs.
  Zhao *et al*, 2017                               C57BL/6 mice        Traumatic brain injury                                   Downregulated caspase-3 and -9 expression                                  ([@b17-br-0-0-1246])
  Liu *et al*, 2017                                HUVECs              Advanced glycation end product induced                   Regulation of Bcl-2 expression                                             ([@b22-br-0-0-1246])
  Lei *et al*, 2014                                SH-SY5Y             β-amyloid induced                                        Regulation of Bcl-2, caspase-3 and -9 expression                           ([@b37-br-0-0-1246])
  Xu *et al*, 2017                                 C57BL/6 mice        Repeated cerebral ischemia reperfusion                   Bcl-2/Bax elevation                                                        ([@b38-br-0-0-1246])
  Xiang *et al*, 2014                              APP/PS1 mice        Transgenic                                               BDNF/TrkB/PI3K/Akt pathway regulation                                      ([@b39-br-0-0-1246])
  D, Resistance to endoplasmic reticulum stress                                                                                                                                                            
  Author, year                                     Study subject       Method                                                   Molecular mechanism                                                        Refs.
  Liao *et al*, 2018                               SD rats             Doxorubicin induced                                      GRP78, CHOP and caspase-12 expression regulation                           ([@b41-br-0-0-1246])
  Niu *et al*, 2018                                SD rats             Bilateral surgical ligation of common carotid arteries   GRP78, CHOP and caspase-12 expression regulation                           ([@b42-br-0-0-1246])
  Zheng *et al*, 2017                              SD rats             Laminectomy performed at T9                              ATF-4, ATF-6, XBP-1, PDI, GRP78, CHOP and cleaved-caspase 12 attenuation   ([@b43-br-0-0-1246])
                                                   HBMECs              Thapsigargin induced                                     ATF-4, ATF-6, XBP-1, PDI, GRP78, CHOP and cleaved-caspase 12 attenuation    
  He *et al*, 2017                                 SD rats             Laminectomy performed at T9                              ATF-4, ATF-6, XBP-1, PDI, GRP78, CHOP and cleaved-caspase 12 attenuation   ([@b44-br-0-0-1246])
                                                   PC12                Thapsigargin induced                                     ATF-4, ATF-6, XBP-1, PDI, GRP78, CHOP and cleaved-caspase 12 attenuation    
  E, Reduced abnormal protein deposition                                                                                                                                                                   
  Author, year                                     Study subject       Method                                                   Molecular mechanism                                                        Refs.
  Peng *et al*, 2010                               3xTg-AD mice        Transgenic                                               Direction of APP processing towards a non-amyloidogenic pathway            ([@b47-br-0-0-1246])
  Peng *et al*, 2012                               AβPP/PS1 mice       Transgenic                                               Tau hyperphosphorylation inhibition                                        ([@b48-br-0-0-1246])
  Chen *et al*, 2018                               C57BL/6 mice        LPS induced                                              Reduction of α-synuclein deposition                                        ([@b16-br-0-0-1246])
  Huang *et al*, 2010                              PC12                MPP^+^ toxicity induced                                  Reduction of α-synuclein deposition                                        ([@b49-br-0-0-1246])

LPS, lipopolysaccharide; SD, Sprague Dawley; JNK, c-Jun N-terminal kinase; HGF, hepatocyte growth factor; PGAM5, PGAM family member 5; RAGE, receptor for advanced glycation end-product; Nrf, nuclear respiratory factor; ARE, antioxidant response element; Keap1, Kelch-like ECH-Associating protein 1; Mash1, mammalian achaete scute homolog-1; TFAM, human mitochondrial transcription factor A; ICR, Institute of Cancer Research; NSC, neural stem cell; BDNF, brain derived neurotrophic factor; TrkB, Tyrosine receptor kinase B; GRP78, glucose regulated protein 78; XBP-1, X-box-binding protein 1; PDI, protein disulfide isomerase; APP, amyloid precursor protein; ATF, activating transcription factory; CHOP, CCAAT-enhancer binding protein homologous protein; MPP^+^, 1-methyl-4-phenylpyridiniumion.
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